Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630720 | 0.83 | HCRTR2 (0.58) | TSHRKEAP1NFE2L2SMN1; SMN2MAPT | |
| SCHEMBL1631672 | 0.83 | HCRTR2 (0.58) | TSHRKEAP1NFE2L2ALDH1A1MAPT | |
| Acetic Acid SCHEMBL1920216 | 0.81 | HCRTR2 (0.56) | TSHRKEAP1NFE2L2SMN1; SMN2MAPT | |
| SCHEMBL1630581 | 0.81 | HCRTR2 (0.56) | TSHRKEAP1NFE2L2SMN1; SMN2MAPT | |
| SCHEMBL1630558 | 0.78 | CRHBP (0.54) | TSHRALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1630949 | 0.77 | KEAP1 (0.87) | KEAP1NFE2L2ALDH1A1TP53MAPT | |
| SCHEMBL1629341 | 0.76 | KEAP1 (0.66) | KEAP1NFE2L2TP53MAPT | |
| SCHEMBL1630305 | 0.75 | KEAP1 (0.71) | KEAP1NFE2L2MAPT | |
| SCHEMBL1039606 | 0.74 | TSHR (0.56) | TSHRKEAP1NFE2L2ALDH1A1MAPT | |
| SCHEMBL1630319 | 0.74 | CRHBP (0.51) | ALDH1A1MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| WO-2009092642-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | TSHR 112/4885KEAP1 1802/4885NFE2L2 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.